Atea Pharmaceuticals Management
Management criteria checks 2/4
Atea Pharmaceuticals' CEO is Jean-Pierre Sommadossi, appointed in Jul 2012, has a tenure of 11.92 years. total yearly compensation is $5.93M, comprised of 11.5% salary and 88.5% bonuses, including company stock and options. directly owns 7.17% of the company’s shares, worth $20.42M. The average tenure of the management team and the board of directors is 3.8 years and 4.8 years respectively.
Key information
Jean-Pierre Sommadossi
Chief executive officer
US$5.9m
Total compensation
| CEO salary percentage | 11.5% |
| CEO tenure | 11.9yrs |
| CEO ownership | 7.2% |
| Management average tenure | 3.8yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
Atea wins FDA Fast Track status for dengue treatment
Sep 26Atea Pharmaceuticals Q2 2022 Earnings Preview
Aug 08Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
May 13
Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Jan 05Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
Nov 25A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Oct 24Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Oct 20U.S. to invest more than $3B to boost development of COVID-19 antiviral drugs
Jun 17Atea Pharmaceuticals, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
May 15Market Sentiment Around Loss-Making Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)
May 13Growth Investors: Industry Analysts Just Upgraded Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Revenue Forecasts By 73%
Apr 08Atea Pharmaceuticals (NASDAQ:AVIR) Is In A Strong Position To Grow Its Business
Mar 06Need To Know: Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Insiders Have Been Buying Shares
Jan 30
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
Compensation vs Market: Jean-Pierre's total compensation ($USD5.93M) is above average for companies of similar size in the US market ($USD1.63M).
Compensation vs Earnings: Jean-Pierre's compensation has increased whilst the company is unprofitable.
CEO
Jean-Pierre Sommadossi (68 yo)
11.9yrs
Tenure
US$5,925,790
Compensation
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.9yrs | US$5.93m | 7.17% $ 20.0m | |
| CFO, Executive VP of Legal & Secretary | 10.5yrs | US$1.96m | 0.80% $ 2.2m | |
| Executive VP of Finance & Chief Accounting Officer | 2.4yrs | US$1.52m | 0.025% $ 69.0k | |
| Chief Development Officer | 3.8yrs | US$2.11m | 0.042% $ 117.1k | |
| Chief Medical Officer | 3.8yrs | US$1.85m | 0.030% $ 84.9k | |
| Senior Vice President of Investor Relations & Corporate Communications | 3.4yrs | no data | no data | |
| Vice President of Marketing | 2.4yrs | no data | no data | |
| Executive Vice President of Chemistry | no data | no data | no data | |
| Executive Vice President of Early Stage Development | no data | no data | no data | |
| Chief Commercial Officer | 5.7yrs | US$1.52m | 0.12% $ 344.3k | |
| Executive VP of Clinical Sciences & Project Management | 4.4yrs | no data | no data | |
| Executive Vice President of Regulatory Affairs | 3.4yrs | no data | no data |
3.8yrs
Average Tenure
61.5yo
Average Age
Experienced Management: AVIR's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 11.9yrs | US$5.93m | 7.17% $ 20.0m | |
| Independent Director | 3.7yrs | US$332.10k | 0.039% $ 109.7k | |
| Independent Director | 9.8yrs | US$324.60k | 0.099% $ 275.2k | |
| Lead Independent Director | 4.8yrs | US$357.10k | 0.96% $ 2.7m | |
| Independent Director | 9.6yrs | US$324.60k | 0.078% $ 217.2k | |
| Independent Director | 3.8yrs | US$327.10k | 0.067% $ 186.8k | |
| Independent Director | 3.1yrs | US$442.10k | 0.039% $ 109.7k |
4.8yrs
Average Tenure
64yo
Average Age
Experienced Board: AVIR's board of directors are considered experienced (4.8 years average tenure).